Aileron Therapeutics Inc - ESG Rating & Company Profile powered by AI
This Sustainability score for Aileron Therapeutics Inc represents its reporting of the United Nations Sustainable Development Goals. The webpage displays a zero-cost E,S&G assessment for Aileron Therapeutics Inc. Other corporations in the rating peer group for Aileron Therapeutics Inc are displayed.
Aileron Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.3; made up of an environmental score of 8.0, social score of 8.0 and governance score of 6.0.
7.3
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 160 | YungShin Global Holding Corp | 7.5 | High |
| 160 | Zentiva SA | 7.5 | High |
| 191 | Aileron Therapeutics Inc | 7.3 | High |
| 191 | Cellectis SA | 7.3 | High |
| 191 | Aurinia Pharmaceuticals Inc | 7.3 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Aileron Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Aileron Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Aileron Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Aileron Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Aileron Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Aileron Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Aileron Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Aileron Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Aileron Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Aileron Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Aileron Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Aileron Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Aileron Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Aileron Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Aileron Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Aileron Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Aileron Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Aileron Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.